Treatment of Steroid Responsive Skin Conditions
TDT-044 is using Transfersome® carriers to deliver corticosteroids for better treatment of dermatoses including psoriasis and eczema.
Psoriasis is an auto-immune disease involving skin inflammation and causing psoriatic plaques. It affects around 2-3% of the population, who are typically treated by topical mid and high potency steroids. Such treatments are limited by the skin atrophying side effects of steroids, however, calling strongly for a safer steroid treatment.
TDT-044 is being developed to achieve a similar effect as the effect of current high potency steroids, but using lower drug dosages and permitting longer treatment, thus significantly improving patients' quality of life.
In addition to higher-potency steroids, a variety of powerful and expensive systemic agents are used to treat the more severe psoriasis patient. These include injected anti-TNF antibodies, oral cyclosporin, and other systemic immunosuppressants. All of these drugs have medium to severe side effects associated with systemic drug presence. The market size for high-potency steroids is approximately $500 million annually. Successfully accessing the medium-potency market, by delivering the intended product profile, could significantly expand the potential market value.